Compare ATYR & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | NMS |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 73.8M |
| IPO Year | N/A | N/A |
| Metric | ATYR | NMS |
|---|---|---|
| Price | $0.84 | $11.98 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 16.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9,628.95 | N/A |
| Revenue Next Year | $156.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $11.07 |
| 52 Week High | $7.29 | $12.25 |
| Indicator | ATYR | NMS |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 33.55 |
| Support Level | $0.82 | $11.84 |
| Resistance Level | $0.85 | $12.00 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 7.78 | 47.73 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.